Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium
Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?
Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium
Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…Abstract Number: 071 • 2023 Pediatric Rheumatology Symposium
Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort
Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…Abstract Number: 045 • 2023 Pediatric Rheumatology Symposium
Patient Reported Outcomes in Pediatric Vasculitis
Background/Purpose: Vasculitis is a group of multisystem, often relapsing diseases that can affect patients through disease activity, damage, and treatment toxicity. Vasculitis in adults often…Abstract Number: L17 • ACR Convergence 2022
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…Abstract Number: 0146 • ACR Convergence 2022
Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis
Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitis, including Giant Cell Arteritis (GCA). Clinical trials with TCZ in GCA were performed with intravenous (iv)…Abstract Number: 0467 • ACR Convergence 2022
All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study
Background/Purpose: Most previous studies have demonstrated a similar overall survival in patients with GCA compared to the background population. However, we have previously reported an…Abstract Number: 0494 • ACR Convergence 2022
Risk for Visual Loss in Patients with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) involves both the cranial and large vessels. Permanent visual loss is a feared complication reported in up to 19% of…Abstract Number: 1082 • ACR Convergence 2022
Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
Background/Purpose: While there is established data regarding the induction and maintenance treatment of systemic or organ threatening granulomatosis with polyangiitis (GPA), there is limited data…Abstract Number: 1557 • ACR Convergence 2022
Microvascular Involvement in Behçet’s Disease: Study of Nailfold Capillaroscopy in Patients from a National Referral Center
Background/Purpose: Ocular and mucocutaneous manifestations of Behçet's disease (BD) are globally recognized and widely studied [Arthritis Rheumatol. 2019 Dec;71(12):2081-2089, Clin Exp Rheumatol. 2020 Sep-Oct;38 Suppl…Abstract Number: 1615 • ACR Convergence 2022
Myocardial Infarction in Patients with Systemic Vasculitis and Population Controls: Characteristics and Overall Mortality
Background/Purpose: The deleterious effect of inflammation combined with glucocorticoid treatment may increase the risk for atherosclerotic events. The aims of this study were to investigate…Abstract Number: 0433 • ACR Convergence 2022
Clustering of Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis – Using a Pre-processed Harmonised Dataset
Background/Purpose: The sub-classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been a long-standing debate. Unsupervised learning has previously been used for partitioning of phenotypic…Abstract Number: 0468 • ACR Convergence 2022
Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in the elderly and large vessel involvement (LV-GCA) occurs in up to 50% of cases.…Abstract Number: 0513 • ACR Convergence 2022
The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: Clinical characteristics and outcomes often differ between children and adults diagnosed with the same rheumatic condition; however, such comparative data is limited in ANCA-associated…
- 1
- 2
- 3
- …
- 20
- Next Page »